Nyrada Inc

NYR

Company Profile

  • Business description

    Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

  • Contact

    180 George Street, Sydney Place
    Level 22/23, Salesforce Tower
    SydneyNSW2000
    AUS

    T: +61 294983390

    https://www.nyrada.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

stocks

Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?

Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks

Higher interest rates boost earnings for ASX real estate platform

Interest rates are driving a spike in property listings.
stocks

After earnings, is Palantir a buy, a sell, or fairly valued?

With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,880.707.700.09%
CAC 407,952.3327.59-0.35%
DAX 4024,139.53184.600.77%
Dow JONES (US)49,760.5656.090.11%
FTSE 10010,276.0510.730.10%
HKSE26,388.4440.530.15%
NASDAQ26,088.20185.92-0.71%
Nikkei 22563,272.11529.540.84%
NZX 50 Index13,063.0617.27-0.13%
S&P 5007,400.9611.88-0.16%
S&P/ASX 2008,630.400.60-0.01%
SSE Composite Index4,242.5728.080.67%

Market Movers